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Abstract 
 
Hypercholesterolemia is a major risk factor for the development and progression of 
cardiovascular diseases including atherosclerosis. A major active ingredient scutellarin, 
from the plant Erigeron breviscapus was investigated for its hypocholesterolemic and 
atheroscleroprotective effects (30 and 100 mg/kg/day, p.o.). The serum lipid profile (total 
cholesterol, triglycerides, high density lipoprotein cholesterol and low density lipoprotein 
cholesterol) was monitored and aortic functions in Sprague-Dawley rats fed with normal 
diet, atherogenic diet or atherogenic diet plus oral administration of either scutellarin or 
simvastatin (a positive control) were tested. It was found that scutellarin markedly 
attenuated the increased serum total cholesterol induced by atherogenic diet. It caused a 
significant reduction in the atherogenic index. In addition, scutellarin administration 
could significantly enhance acetylcholine-induced nitrate/nitrite production, increase the 
gene expression of endothelial nitric oxide synthase and improve acetylcholine-induced 
endothelium-dependent vasorelaxation in rat isolated aortas. These data revealed that 
scutellarin could reduce the atherogenic properties of dietary cholesterol in rats. However, 
whether scutellarin’s atheroscleroprotective potential targets endothelial function directly 
or indirectly on its antioxidative activity remains to be determined. 
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Introduction 
 
Atherosclerosis is the leading cause of death in developed countries and the incidence 
rate is increasing in other parts of the world [1,2]. Hypercholesterolemia (high blood total 
cholesterol) is a dominant risk factor for the development and progression of 
atherosclerosis and other related cardiovascular diseases which have emerged as a major 
health problem in many countries [2,3]. A high cholesterol diet is a major contributor to 
an unbalanced lipoprotein metabolism and associates with an increased prevalence of 
atherosclerosis [3]. 
 
In hypercholesterolemia and atherosclerosis, the physiological activity of nitric oxide 
(NO) is reduced and this resulted in impairment of the endothelium-dependent 
vasodilation, platelet aggregation enhancement and increased endothelial adhesiveness 
for monocytes [4]. Endothelial dysfunction is recognized as the basic mechanism for 
initiation and maintenance of atherosclerosis [5]. Therefore, the protection of endothelial 
integrity by elimination of certain risk factors via lipid lowering agents has been proven 
to be effective in restoring endothelial function and in slowing the progress of the disease 
[6].  
 
Scutellarin, 7-(-D-glucopyranuronosyloxy)-5,6-dihydroxy-2-(4-hydroxyphenyl)-4-H-1- 
benzopyran-4-one (C21H18O12) (Fig. 1), is one of the active components isolated from a 
perennial wild plant distributed in southwest China, Erigeron breviscapus (Vant.) 
Hand.-Mazz. (Dengzhanxixin), which belongs to the family of Compositae and has been 
used in clinical settings to treat cerebrovascular accident patients for many years [7]. In 
recent years, it was reported that scutellarin possessed anticoagulatory [8], antioxidative 
[9], anti-inflammatory [10], neuroprotective [11], vasorelaxation [12] as well as 
cardiovascular and cerebrovascular ischemia protective effects [13,14]. Despite the broad 
therapeutic uses of Erigeron breviscapus, there have been no reports on its effects on the 
reduction of lipid levels and atheroscleroprotection. 
 
Therefore, an investigation was studied on scutellarin for any effect on high cholesterol 
diet-induced hypercholesterolemic rats, in particular the serum lipid profile [total 
cholesterol, triglycerides, high density lipoprotein cholesterol (HDL) and low density 
lipoprotein cholesterol (LDL)]. To investigate the protective role of scutellarin treatment 
under hypercholesterolemic condition, further investigations were carried out on the 
endothelium-dependent vasorelaxation, acetylcholine-induced nitrate/nitrite production 
[presumably NO production] and endothelial nitric oxide synthase (eNOS) mRNA 
expression of isolated aortas from rats with or without treatment with scutellarin. The 
effect of simvastatin, a known hypocholesterolemic and hypolipidemic drug, was also 
used for comparison. 
 
Materials and Methods 
 
Chemicals 
Scutellarin was purchased as a yellow powder (>98% purity, formula weight 464.4) from 
Xi’an Guanyu Bio-Technique Co. Ltd (Xi’an, China) while simvastatin 20 mg tablets 
(10% purity, the content was confirmed by HPLC) were purchased from Hangzhou MSD 
Pharmaceutical Co. Ltd. (Hangzhou, China). Phenylephrine, acetylcholine, 
N
ω
-nitro-L-arginine methyl ester (L-NAME), indomethacin and neostigmine were 
purchased from Sigma Chemicals Co. (St. Louis, MO, USA). NO kit was from Nanjing 
Keygen Biotech. Co. Ltd. (Nanjing, China). All the other chemicals used were of 
analytical grade. 
 
Animals and experimental treatment 
Male Sprague-Dawley rats (170 ± 10 g), supplied by Guangdong Provincial Medical 
Laboratory Animal Center (Guangzhou, PR of China), were housed separately (4 
animals/cage) under a temperature controlled (25 ± 2 °C) room with a regular 12 hr light: 
12 hr dark cycle.  After one week, the rats were randomly assigned to one of five 
experimental groups (n = 8) for an additional 38 days. These groups were control group 
(Control), high cholesterol diet group (HCD), simvastatin (10 mg/kg/day, p.o.) treated 
group (SIM), low dose scutellarin (30 mg/kg/day, p.o.) treated group (SL) and high dose 
scutellarin (100 mg/kg/day, p.o.) treated group (SH). The control group was fed with 
standard normal rat chow with protein (~14%), fat (~10%) and carbohydrate (~76%) 
while the other groups were fed with HCD, which is a standard rat chow supplemented 
with 1% cholic acid, 2% pure cholesterol and 5.5% oil. The rats were administered with 
distilled water or their corresponding drugs by oral gavage (20 mL/kg) once every 
morning for 38 days. At the end of the experimental period, the rats were fasted overnight 
and killed by cervical dislocation. Blood samples and aortas were then collected for 
further analysis. All experiments were approved by the Ethical Committee of the Hong 
Kong Polytechnic University.  
 
Analysis of lipid levels in blood samples 
Immediately after cervical dislocation, blood was collected in chilled centrifuge tubes by 
cardiac puncture. The blood was then centrifuged (4500 rpm) at 4 °C for 15 min and 
serum was collected. Total serum cholesterol, triglycerides, LDL and HDL were 
measured by using the Keygen’s reagents.  
 
Isolation of thoracic aorta 
At the end of the treatment period, the rats were sacrificed and their thoracic aortas were 
immediately placed in 4 °C Tyrode's solution of the following composition: NaCl 118 
mM, KCl 4.7 mM, KH2PO4 1.2 mM, NaHCO3 25 mM, glucose 11 mM, CaCl2 2.5 mM, 
and MgSO4 1.2 mM. The isolated aorta from each animal was cut into three ring 
segments with any fat and connective tissue removed. One ring from each aortic 
preparation was used for isometric tension measurement (aortic ring ~3 mm), in vitro 
nitrate/nitrite production (aortic ring ~15 mm) and real-time PCR analysis (aortic ring 
~15 mm).   
 
Measurement of the isometric tension of the isolated thoracic aorta 
One of the ring segments was mounted in 5 ml organ baths filled with Tyrode's solution 
(37 °C, gassed with 95% O2 and 5% CO2 mixture), under passive tension of 1.2 g for 60 
min. After 60 min of equilibration, the aortic rings were challenged with 60 mM KCl 
twice to ensure a suitable contractile set up of the preparation. The contractile response 
(isometric tension, in g) was measured. To investigate the relaxant effects of 
acetylcholine on isolated aorta, the preparations were pre-contracted with 1 M 
phenylephrine in the presence of 1 M indomethacin (a nonselective cyclo-oxygenase 
inhibitor) and 1 M neostigmine (an anticholinesterase). After a steady-state contraction 
was established, cumulative concentrations (10 nM – 10 M) of acetylcholine were 
added to the organ bath.  
 
In vitro nitrate/nitrite production in the isolated thoracic aorta 
To evaluate the endothelial damage in blood vessels caused by high cholesterol diet, in 
vitro nitrate/nitrite production in the aortic ring was tested to estimate NO production.  
The isolated aortas were washed twice with Tyrode's solution, and then cut into 15mm 
segments (weight = 0.03 – 0.04 g). The segments were incubated in a 24-well plate 
(containing 2 mL Tyrode's solution per well) with 1 M acetylcholine and 1 M 
neostigmine. After incubation (37 °C) for 2 hr, each segment was blotted dry and 
weighed and the incubated culture solution of each well was collected in a separate 
microcentrifuge tube. The solution of each tube was subsequently dried by vacuum 
freeze-drying and the resulting pellets were re-dissolved with 300 L of distilled water. 
Nitrate/nitrite levels were measured using the Keygen’s NO kit. The absorbance was 
determined using the spectrophotometer at 540 nm. The concentrations of nitrate/nitrite 
were calculated following the instruction of the kit. 
 
Real-time polymerase chain reaction analysis 
Isolated thoracic aortas were homogenized and total RNA was extracted using Trizol 
reagent (Life Technologies Inc., Rockville, MD, USA) for the determination of gene 
expression levels in various groups. 3.5 g of total RNA was reverse transcribed into 
cDNA using RevertAid™ first strand cDNA synthesis kit (Fermentas). Real-time PCR 
was performed with an ABI PRISM
®
 7000 Sequence Detection System with 
SYBR
®
GreenER
TM 
qPCR SuperMix for ABI PRISM
®
 (Invitrogen) in 20 L of total 
reaction mixture. The primers for eNOS and glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) were purchased from Shanghai GeneCore Bio Technologies Co. Ltd. (China) 
(Table 1). Expression levels of the cDNA of interest were related to an internal standard: 
housekeeping gene (GAPDH), to correct for differences in quantity and quality between 
different RNA samples.  
 
Statistical analysis 
Data was expressed as means ± S.E.M. and n denotes the number of replications for each 
data point. After validation of each parameter for homogencity of variance, the 
differences between groups were assessed by one-way analysis of variance using SPSS 
(Version 12) software package for Windows (Chicago, IL, USA). Post hoc testing was 
performed for intergroup comparisons using the least significance difference test; with P 
values of < 0.001, < 0.01 and < 0.05 are indicated in the figures or tables.  
Results 
 
The lipid profiles: serum total cholesterol, triglycerides, HDL and LDL from various rat 
groups are summarized in Table 2. Elevated serum total cholesterol and LDL were 
observed in the HCD. Treatment with simvastatin (10 mg/kg/day) and scutellarin (both 
30 mg/kg/day and 100 mg/kg/day) altered the lipid profiles to normal levels and a notable 
increase in serum HDL/LDL ratio was observed. The serum total cholesterol was 
significantly reduced in the SIM (3.75 ± 0.40 mmol/L, P < 0.001), SL (4.86 ± 0.32 
mmol/L, P < 0.05) and SH (4.34 ± 0.21 mmol/L, P < 0.01), as compared with that in the 
HCD (5.73 ± 0.36 mmol/L). However, total cholesterol in serum did not return to normal 
level (2.25 ± 0.05 mmol/L) in all treatment groups. The notable increase in the ratio of 
HDL/LDL among treatment groups was brought about by a markedly increase of HDL. 
The levels of HDL in all treatment groups were comparable to the level in the control 
group (P > 0.05). A high cholesterol diet significantly up-regulated LDL content but not 
the level of triglycerides in serum. Both simvastatin and scutellarin treatments have no 
significant effect on the levels of LDL and triglycerides (P > 0.05).  
 
Further analysis of the impact of serum lipid profiles on the progression of 
atherosclerosis, the atherogenic index [(total serum cholesterol  HDL) / HDL] which 
measures coronary heart disease risk was calculated. It was found that elevated 
atherogenic index was observed in the HCD. There was a significant decrease in the 
atherogenic indexes in both the SIM and SH (Fig. 2) which suggested the 
atheroscleroprotective potential of simvastatin or scutellarin in the current experimental 
setting. The atherogenic indexes were 2.69 ± 0.32 in the SIM and 2.58 ± 0.13 in the SH 
as compared to the HCD with 3.63 ± 0.26. The indexes for both the SIM and SH were 
close to the level of the control group (2.26 ± 0.32). 
 
To evaluate the protective effect of drug administration on vascular endothelial activity, 
the thoracic aorta (with intact endothelium) was isolated for various analyses. When 
phenylephrine (1 M)-induced contraction reached a steady condition, acetylcholine was 
added cumulatively to the aortic preparation. Acetylcholine elicited a concentration (10 
nM  10 M)-dependent aortic relaxation of various groups of rats with ~55  80% 
maximum relaxation at 10 M (n = 6  8) (Fig. 3). However, a significant smaller 
magnitude of relaxation caused by acetylcholine was observed from HCD rats compared 
to those observed in other groups. Scutellarin (30 mg/kg/day & 100 mg/kg/day) dose 
dependent improved the acetylcholine-induced relaxation in rats with high cholesterol 
diet. There was amelioration in the acetylcholine-induced relaxation in animals treated 
with scutellarin (100 mg/kg/day) and simvastatin (10 mg/kg/day).  
 
The effect of drug treatments on high cholesterol diet-induced damage on aortic 
endothelial cells was also investigated. The isolated aortic rings from various groups 
were tested with regard to their effect on nitrate/nitrite production. Without acetylcholine 
(1 M), aortic rings released undetectable levels of nitrate/nitrite after 2 hr incubation 
(data not shown). When acetylcholine (1 M) was added to the incubation medium, 
nitrate/nitrite production in control group dramatically increased to 0.86 ± 0.21nmol/mg 
of aortic tissue for the 2 hr incubation period. The effect of acetylcholine on nitrate/nitrite 
production could be abolished by a NOS inhibitor, L-NAME (20 M) (data not shown). 
It was found that high cholesterol diet markedly attenuated nitrate/nitrite production (0.25 
± 0.05 nmol/mg of tissue, P < 0.05). As shown in Fig. 4, all treatment groups significantly 
potentiated nitrate/nitrite production. The increase in nitrate/nitrite production for 
scutellarin was in a dose-dependent manner.  
 
Change in the gene expression of eNOS was also examined (Fig. 5). The gene expression 
level of eNOS in the aortas from HCD group was markedly suppressed (P < 0.001); 
whereas treatment of simvastatin (10 mg/kg/day) and scutellarin (100 mg/kg/day) could 
significantly increase eNOS expression level back to the level of control group (1.81 ± 
0.324) (P < 0.05). However, animals treated with scutellarin (30 mg/kg/day) showed no 
significant enhancement in the gene expression of eNOS. 
 
Discussion 
 
This study described for the first time that scutellarin has hypocholesterolimic effect and 
is orally active. In the present study, we have illustrated that oral scutellarin 
administration significantly reduced serum total cholesterol and increased serum 
HDL/LDL ratio. In addition, the elevated atherogenic index induced by atherogenic diet 
was reversed thus suggesting atheroscleroprotection by scutellarin. Although the testing 
dosage for scutellarin was up to 100 mg/kg/day, it can be considered as non-toxic for the 
fact that intraperitoneal LD50 values in mice is 2402 mg/kg [13]. To evaluate the 
applicability of the current animal model, simvastatin (positive control) was used. It is a 
potent hypocholesterolemic and hypolipidemic drug of statin series and is commonly for 
the treatment of coronary heart disease, hypercholesterolemia and hyperlipidemia [15]. In 
this study, simvastatin has been shown to improve serum lipid profile and atherogenic 
index similar to the effects seen with scutellarin. However, the effects of simvastatin in 
the present study were associated with an increase in HDL level but no change in LDL 
level in animals fed with atherogenic diet. This is different from the function of statins in 
lowering LDL. This warrants further study in the current experimental setting. 
 
In the current study, the HCD had abnormal serum lipid levels with significantly 
increased total cholesterol and LDL but no significant changes in triglyceride and HDL 
levels. This is consistent with previous studies with similar experimental settings [3,16]. 
In fact, elevated plasma total cholesterol and LDL levels are significant enough to 
demonstrate the atherogenic effect of the model since both parameters play a significant 
role in atherosclerosis development and subsequent coronary heart disease [17].  
 
Hypercholesterolemia and atherosclerosis have a close relationship with vascular 
dysfunction [5]. The present findings showed endothelial dysfunction in aortic rings from 
hypercholesterolemic rats. Vascular relaxation in response to acetylcholine was clearly 
blunted in aortas from the HCD. This provides supporting evidence to other studies 
where hypercholesterolemia and early stages of atherosclerosis in experimental animals 
and humans, the most common vascular functional abnormality is a reduction of 
endothelium-dependent relaxation [18]. Scutellarin could prevent the high cholesterol 
diet-induced reduction of eNOS gene expression. This in turn, increased the 
acetylcholine-induced nitrate/nitrite production and acetylcholine-induced vasorelaxation 
in aortic rings dose dependently.  
 
NO responds to various pathophysiological stimuli in order to protect the integrity of the 
vasculature [19]. It is rapidly oxidized to nitrite/nitrate. The measurement of plasma 
nitrite/nitrate after an overnight fast was used as an index of NO synthase (NOS) activity 
[20]. Indeed, either activation or inhibition of NOS activity was associated with 
corresponding increases or decreases in circulation nitrite concentrations [21]. However, 
it should be noted that approximately 70% of plasma nitrite has been shown to be derived 
from NOS activity in the endothelium [21]. To enhance the accuracy of NOS activity 
estimation, we adopted a method to measure acetylcholine-induced nitrate/nitrite 
production in vitro instead of monitoring nitrite concentration in the circulation. 
 
Atherogenic lipoprotein, LDL, was shown to increase eNOS generation of superoxide 
anion [22]. An increase in reactive oxygen species (ROS) resulted in oxidative stress and 
cellular oxidative damage [23]. In a hypercholesterolemic condition, increased ROS in 
the endothelium increases NO breakdown [24]. Scutellarin possesses a potent 
antioxidative activity and protected cells (including endothelium) from oxidative damage 
[25]. It was demonstrated as a good ROS scavenger [8,26]. Therefore, scutellarin could 
protect the vasculature through its antioxidative activity. 
 
In the present study, scutellarin treatment dose dependently improved 
acetylcholine-induced relaxation on aortic rings. This can be explained by the 
up-regulation of eNOS RNA expression and/or increase in acetylcholine-induced 
nitrate/nitrite production, which represented an increase in NO availability. Scutellarin 
was shown to increase eNOS expression in a rat model of cerebral ischemia/reperfusion 
[14]. However, whether the vasoprotective effect is due to the up-regulation of eNOS 
gene, the antioxidative activity of scutellarin or both is presently unclear and awaits 
further investigation. In the HCD group, eNOS RNA expression was down-regulated in 
isolated aorta. However, several studies have shown that cardiovascular risk factors, 
including hypercholesterolemia are associated with an increase rather than a decrease in 
eNOS expression [27,28]. The reason for a decrease in NO availability is more likely 
related to eNOS dysfunction (eNOS uncoupling), which in many cases is resulted from a 
reduced availability of tetrahydrobiopterin, an essential co-factor for NOS [28]. eNOS 
uncoupling will lead to superoxide and H2O2 production [29]. The discrepancy in eNOS 
RNA expression warrants further study.  
 In conclusion, the current results indicate for the first time that scutellarin possess 
prominent hypocholesterolemic and atheroscleroprotective effects. The effects may be 
brought about by scutellarin on the gene expression of eNOS in endothelial cells, 
antioxidative activity or both. Confirmatory studies in other models would provide more 
evidence of scutellarin's effects. 
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Figure legends 
 
Fig. 1 The chemical structure of scutellarin. *Chiral center. 
 
Fig. 2 The antherogenic indexes of animals from the Control, HCD, SIM, SL and SH. 
Data are expressed as means ± SEM, n = 5 8. #P < 0.05 represents significant 
differences when compared with the Control group. *P < 0.05 and **P < 0.01 represent 
significant differences when compared with the HCD. 
 
Fig. 3 The concentration-response curves to acetylcholine are expressed as decrease in 
(percentage) steady state tension obtained with 1 M phenylephrine precontracted 
thoracic aortic rings from the Control, HCD, SIM, SL and SH. Data are expressed as 
means ± SEM, n = 6 - 8. *P < 0.05 and **P < 0.01 represent significant differences when 
compared with the Control group. 
 
Fig. 4 In vitro nitrate/nitrite production from isolated aortas under challenging with 
acetylcholine (1 M). Data are expressed as means ± SEM, n = 6 – 8. #P < 0.05 
represents significant differences when compared with the Control group. *P < 0.05 
represents significant differences when compared with the HCD. 
 
Fig. 5 Real time RT-PCR analysis of the gene expressions of eNOS in isolated aortas 
from the Control, HCD, SIM, SL and SH. The expression level of each gene was 
normalized to that of the GAPDH gene. Data are expressed as means ± SEM, n = 3 – 8. 
#
P < 0.05 represents significant differences when compared with the Control group. *P < 
0.05 represents significant differences when compared with the HCD. 
 
 
 
 
 Table 1 The primer sets used for real-time PCR 
Gene Forward primer Reverse primer 
Product 
size 
(bp) 
Accession 
number 
eNOS 5’GGATTCTGGCAAGACCGATTAC3’ 5’GGTGAGGACTTGTCCAAACACT3’ 159 U18336 
GAPDH 5’TGCACCACCAACTGCTTAG3’ 5’AGTGGATGCAGGGATGATGT3’ 180 NM_017008 
 
Table 2 Serum lipid levels of rats in Control, HCD, SIM, SL and SH groups 
Animals 
groups 
Control HCD SIM SL SH 
Total 
cholesterol 
(mmol/L) 
2.25 ± 0.05 5.73 ± 0.36
###
 
3.75 ± 0.40
###, 
*** 
4.86 ± 0.32
###, 
* 
4.34 ± 0.21
###, 
** 
Triglyceride 
(mmol/L) 
0.71 ± 0.03 0.73 ± 0.04 0.73 ± 0.06 0.83 ± 0.04 0.70 ± 0.06 
LDL 
(mmol/L) 
0.29 ± 0.05 0.90 ± 0.07
###
 0.92 ± 0.12
###
 0.95 ± 0.11
###
 0.83 ± 0.04
###
 
HDL 
(mmol/L) 
1.15 ± 0.11 0.62 ± 0.08 1.38 ± 0.09*** 1.29 ± 0.07*** 1.31 ± 0.06*** 
Data are expressed as means ± SEM, n = 3 – 8.  
###
p < 0.001 represents significant differences when compared with the Control group. 
*p < 0.05 represents significant differences when compared with the HCD group. 
**p < 0.01 represents significant differences when compared with the HCD group. 
***p < 0.001 represents significant differences when compared with the HCD group. 
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Fig. 3. 
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Fig. 4. 
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Fig. 5. 
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